104 Chapter 3 SUPPLEMENTARY Supplementary Table 1. Outcome measures and associated references used in meta-analysis. A minimum of 5 articles was required for inclusion of a defined outcome measure in the meta-analysis. References that did not include a quantitative outcome measure or did not report essential study characteristics such as number of animals and standard deviation/error are also shown in “References in systematic review but not used in Meta-Analysis”. Immune Factor References used in Meta-Analysis References in systematic review but not used in Meta-Analysis Blood CCL11 (eotaxin) 88, 108, 112, 118, 143, 305 Blood CCL2 (MCP-1) 86, 88, 95, 98, 99, 105, 111, 112, 118, 119, 142, 150, 185, 198, 212, 214, 215, 221, 225, 245, 266, 270, 305, 314, 351, 358, 399, 400, 407, 423, 424, 510 452, 473, 493 Blood CCL3 (MIP-1α) 88, 89, 98, 108, 112, 118, 130, 266, 302, 305 Blood CCL4 (MIP-1β) 88, 98, 108, 112, 118, 266, 302, 305 Blood CRP (c-reactive protein) 180, 213, 292, 330, 349, 358, 384, 386, 401, 418 165, 496 Blood CXCL1 (GROα) 88, 89, 98, 105, 108, 112, 118, 119, 128, 130, 142, 185, 245, 266, 270, 302, 305, 365, 401, 407, 511 99, 170, 185, 473, 499 Blood CXCL2 (MIP-2) 98, 216, 266, 365, 379, 511 99, 143, 170, 185 Blood CXCL8 (IL-8) 86, 98, 185, 216, 266, 365, 379, 511 113, 146, 454 Blood G-CSF 88, 89, 98, 108, 112, 118, 119, 130, 142, 240, 245, 268, 282, 305, 367, 368, 407 143 Blood GM-CSF 88, 89, 97, 98, 102, 108, 112, 118, 119, 130, 266, 352 Blood Histamine 91, 121, 172, 220, 281, 345, 372, 415, 416 415, 476, 481 Blood HMGB1 126, 193, 258, 297, 344, 348, 373, 404, 421 499 Blood IFN-γ 86, 88, 89, 97, 98, 102, 108, 112, 118, 130, 131, 193, 224, 229, 230, 251, 264, 266, 314, 322, 331, 349, 375, 423 474, 512
RkJQdWJsaXNoZXIy MTk4NDMw